Biosimilar, biobetter and next generation therapeutic antibodies.
作者信息
Beck Alain
出版信息
MAbs. 2011 Mar-Apr;3(2):107-10. doi: 10.4161/mabs.3.2.14785. Epub 2011 Mar 1.
Abstract
摘要
相似文献
1
Biosimilar, biobetter and next generation therapeutic antibodies.生物类似药、生物优化药及下一代治疗性抗体。
MAbs. 2011 Mar-Apr;3(2):107-10. doi: 10.4161/mabs.3.2.14785. Epub 2011 Mar 1.
2
Implementation of the biosimilar pathway: economic and policy issues.生物类似药途径的实施：经济与政策问题
Seton Hall Law Rev. 2011;41(2):511-57.
3
Equivalence and regulatory approaches of nonbiological complex drug products across the United States, the European Union, and Turkey.美国、欧盟和土耳其非生物复合药品的等效性及监管方法。
Ann N Y Acad Sci. 2017 Nov;1407(1):26-38. doi: 10.1111/nyas.13505. Epub 2017 Nov 1.
4
How similar do 'biosimilars' need to be?生物类似药需要多相似？
Nat Biotechnol. 2004 Nov;22(11):1357-9. doi: 10.1038/nbt1104-1357.
5
Regulatory considerations for generic or biosimilar low molecular weight heparins.普通或生物类似物低分子量肝素的监管考量
Curr Drug Discov Technol. 2012 Jun 1;9(2):137-42. doi: 10.2174/1570163811209020137.
6
7
SuperGenerics: a better alternative for biogenerics.超级仿制药：生物仿制药的更佳替代品。
Drug Discov Today. 2005 Apr 15;10(8):533-5. doi: 10.1016/S1359-6446(05)03410-0.
8
Decision Science for Generic Drug Development and Review.仿制药开发与审评的决策科学
J Clin Pharmacol. 2019 Sep;59(9):1249-1251. doi: 10.1002/jcph.929. Epub 2019 May 14.
9
Progress and Hurdles for Follow-on Biologics.生物类似药的进展与障碍
N Engl J Med. 2015 Jun 18;372(25):2380-2. doi: 10.1056/NEJMp1504672. Epub 2015 May 6.
10
The similarity question for biologicals and non-biological complex drugs.生物制品和非生物复杂药物的相似性问题。
Eur J Pharm Sci. 2015 Aug 30;76:10-7. doi: 10.1016/j.ejps.2015.04.010. Epub 2015 Apr 23.
引用本文的文献
1
Characterization of pritumumab in murine models and primate safety study.帕妥珠单抗在小鼠模型中的特性及灵长类动物安全性研究。
Sci Rep. 2025 Mar 25;15(1):10178. doi: 10.1038/s41598-025-95360-9.
2
A novel protein for bioremediation of gadolinium waste.一种用于钆废物生物修复的新型蛋白质。
Protein Sci. 2025 Apr;34(4):e70101. doi: 10.1002/pro.70101.
3
Monoclonal antibodies: From magic bullet to precision weapon.单克隆抗体：从“魔弹”到“精准武器”。
Mol Biomed. 2024 Oct 11;5(1):47. doi: 10.1186/s43556-024-00210-1.
4
Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies.单克隆抗体和下一代抗体的最新进展。
Immunohorizons. 2023 Dec 1;7(12):886-897. doi: 10.4049/immunohorizons.2300102.
5
Current state of molecular and metabolic strategies for the improvement of L-asparaginase expression in heterologous systems.用于提高异源系统中L-天冬酰胺酶表达的分子和代谢策略的当前状态。
Front Pharmacol. 2023 Jun 22;14:1208277. doi: 10.3389/fphar.2023.1208277. eCollection 2023.
6
Biosimilar or Not: Physicochemical and Biological Characterization of MabThera and Its Two Biosimilar Candidates.生物类似药与否：美罗华及其两种生物类似药候选药物的理化和生物学特性
ACS Pharmacol Transl Sci. 2021 Mar 12;4(2):790-801. doi: 10.1021/acsptsci.0c00225. eCollection 2021 Apr 9.
7
Similar biologics in India: A story of access or potential for compromise?印度的类似生物制剂：是可及性的故事还是存在妥协的可能性？
Indian J Med Res. 2020 Nov;152(5):456-467. doi: 10.4103/ijmr.IJMR_43_18.
8
Innovative approaches to biologic development on the trail of CT-P13: biosimilars, value-added medicines, and biobetters.在 CT-P13 的研发道路上的生物开发的创新方法：生物类似药、增值药物和生物改良药。
MAbs. 2021 Jan-Dec;13(1):1868078. doi: 10.1080/19420862.2020.1868078.
9
Glycoproteomics Technologies in Glycobiotechnology.糖组学技术在糖生物技术中的应用。
Adv Biochem Eng Biotechnol. 2021;175:413-434. doi: 10.1007/10_2020_144.
10
Me-too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists.Me-too药物：历史、定义、实例及其与药品短缺和基本药物清单的相关性。
Br J Clin Pharmacol. 2020 Nov;86(11):2114-2122. doi: 10.1111/bcp.14327. Epub 2020 May 13.
本文引用的文献
1
GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins.甘福菲的技术可控制重组治疗性蛋白的糖基化。
Expert Opin Drug Discov. 2010 Jan;5(1):95-111. doi: 10.1517/17460440903413504. Epub 2009 Dec 1.
2
6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.2010 年第六届欧洲抗体大会：2010 年 11 月 29 日-12 月 1 日，瑞士日内瓦。
MAbs. 2011 Mar-Apr;3(2):111-32. doi: 10.4161/mabs.3.2.14788. Epub 2011 Mar 1.
3
The future of anti-CD20 monoclonal antibodies: are we making progress?抗 CD20 单克隆抗体的未来：我们是否在取得进展？
Blood. 2011 Mar 17;117(11):2993-3001. doi: 10.1182/blood-2010-07-298356. Epub 2011 Jan 5.
4
Hearing shines spotlight on biosimilar controversies.听证会聚焦生物类似药争议。
Nat Rev Drug Discov. 2010 Dec;9(12):905-6. doi: 10.1038/nrd3325.
5
Antibody-based therapeutics to watch in 2011.2011 年值得关注的抗体类药物治疗。
MAbs. 2011 Jan-Feb;3(1):76-99. doi: 10.4161/mabs.3.1.13895. Epub 2011 Jan 1.
6
Phase 1 study of anti-epidermal growth factor receptor monoclonal antibody in patients with solid tumors.表皮生长因子受体单克隆抗体在实体瘤患者中的 1 期研究。
MAbs. 2011 Jan-Feb;3(1):67-75. doi: 10.4161/mabs.3.1.14021. Epub 2011 Jan 1.
7
The next generation of antibody-drug conjugates comes of age.新一代抗体药物偶联物已走向成熟。
Discov Med. 2010 Oct;10(53):329-39.
8
Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats.IgG1 的电荷变异体：分离、鉴定、体外结合特性和在大鼠体内的药代动力学。
MAbs. 2010 Nov-Dec;2(6):613-24. doi: 10.4161/mabs.2.6.13333. Epub 2010 Nov 1.
9
Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.运用先进的液相色谱和质谱技术对候选生物类似药与创新型单克隆抗体进行快速比较。
MAbs. 2010 Jul-Aug;2(4):379-94. doi: 10.4161/mabs.11986. Epub 2010 Jul 1.
10
Strategies and challenges for the next generation of therapeutic antibodies.下一代治疗性抗体的策略与挑战。
Nat Rev Immunol. 2010 May;10(5):345-52. doi: 10.1038/nri2747.
Zotero 插件